Becton Dickinson, PharMingen and LeukoSite Sign License Agreement for Chemokines and Receptors.SAN JOSE, Calif.--(BW HealthWire)--Oct. 8, 1997--Becton Dickinson and Company of Franklin Lakes, New Jersey Franklin Lakes is a borough in Bergen County, New Jersey, United States. The Franklin Lakes zip code is 07417. As of the United States 2000 Census, the borough population was 10,422. through its operating unit Becton Dickinson Immunocytometry Systems (BDIS BDIS Broadcast Disconnect (AT&T) ) of San Jose, and subsidiary PharMingen in San Diego, today announced that they have reached an agreement for a worldwide exclusive license to certain research and diagnostic reagents developed at LeukoSite Inc. of Cambridge, Mass. Under the terms of the agreement, LeukoSite grants to BDIS and PharMingen the rights to commercialize antibodies to several chemokine chemokine /che·mo·kine/ (ke´mo-kin) any of a group of low molecular weight cytokines identified on the basis of their ability to induce chemotaxis or chemokinesis in leukocytes (or in particular populations of leukocytes) in inflammation. and chemokine receptors, including CCR 1. CCR - condition code register. 2. CCR - (Database) concurrency control and recovery. 5, the co-receptor for HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , for research use. BDIS and PharMingen also receive an exclusive option to develop in vitro diagnostics In vitro diagnostic (IVD) tests are medical tests conducted in a test tube, or more generally in a controlled environment outside a living organism. In vitro means in glass in Latin. based on these reagents. "This is the first key joint license agreement concluded by BDIS and PharMingen, and it demonstrates our commitment to become the biomedical community's global partner from discovery to diagnosis," said Deborah J. Neff, president of BDIS. "We are particularly pleased to establish a relationship with LeukoSite, a recognized leader in chemokines, chemokine receptors and monoclonal antibodies." The financial terms of the agreement were not disclosed. PharMingen develops, manufactures and sells high quality antibodies and reagents for immunology, cell biology and molecular biology research. Through aggressive internal product development programs and technology licensing efforts, PharMingen has introduced more than 2,500 products in the 10 years since the company was founded. The company of 260 employees is headquartered in San Diego, with offices in Hamburg, Germany and Mississauga (Ontario), Canada. Becton Dickinson pioneered leading-edge cell analysis in 1973 with the introduction of FACS FACS Fellow of the American College of Surgeons. FACS abbr. Fellow of the American College of Surgeons FACS fluorescence-activated cell sorter. , the first commercially available fluorescence-activated cell sorter. Since then, BDIS has become the worldwide leader in flow cytometry systems for both the research and clinical markets. Included in the company's product line are sophisticated flow cytometers and cell sorters, advanced applications and data management software, and a wide range of reagents that allow users to analyze, isolate and characterize immune cells from blood and tissue. CONTACT: LeukoSite Inc., Cambridge, Mass. Gus Lawlor, 617/621-9350 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion